Which has stronger earnings & valuation, ALDX or IKT?

Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aldeyra Therapeutics N/A N/A -$33.85M -$0.39 N/A Inhibikase Therapeutics N/A N/A -$48.26M -$0.43 N/A

Is ALDX or IKT more profitable?

Inhibikase Therapeutics' return on equity of -42.80% beat Aldeyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -53.14% -34.94% Inhibikase Therapeutics N/A -42.80% -40.58%

Which has better earnings and valuation, TTRX or ALDX?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Turn Therapeutics N/A N/A -$3.19M -$0.29 N/A Aldeyra Therapeutics N/A N/A -$33.85M -$0.39 N/A

Is TTRX or ALDX more profitable?

Aldeyra Therapeutics' return on equity of -53.14% beat Turn Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Turn Therapeutics N/A -230.84% -53.19% Aldeyra Therapeutics N/A -53.14% -34.94%

Does the media refer more to AMRN or ALDX?

In the previous week, Amarin's average media sentiment score of 1.87 equaled Aldeyra Therapeutics'average media sentiment score. Company Overall Sentiment Amarin Very Positive Aldeyra Therapeutics Very Positive

Which has preferable valuation and earnings, ALDX or ZNTL?

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aldeyra Therapeutics N/A N/A -$33.85M -$0.39 N/A Zentalis Pharmaceuticals N/A N/A -$137.06M -$1.95 N/A

Is ALDX or ZNTL more profitable?

Aldeyra Therapeutics' return on equity of -53.14% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -53.14% -34.94% Zentalis Pharmaceuticals N/A -70.18% -51.46%

Aldeyra Therapeutics (ALDX) Competitors

$1.36 -0.02 (-1.45%)

Closing price 04:00 PM Eastern

Extended Trading

$1.42 +0.06 (+4.34%)

As of 07:30 PM Eastern

Compare

ALDX vs. IKT, VNDA, TTRX, AMRN, and ZNTL

Should you buy Aldeyra Therapeutics stock or one of its competitors? Aldeyra Therapeutics's main competitors and comparable companies include Inhibikase Therapeutics (IKT), Vanda Pharmaceuticals (VNDA), Turn Therapeutics (TTRX), Amarin (AMRN), and Zentalis Pharmaceuticals (ZNTL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aldeyra Therapeutics compare to Inhibikase Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Aldeyra Therapeutics presently has a consensus price target of $5.50, indicating a potential upside of 304.41%. Inhibikase Therapeutics has a consensus price target of $5.40, indicating a potential upside of 134.78%. Given Aldeyra Therapeutics' higher probable upside, research analysts plainly believe Aldeyra Therapeutics is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

Aldeyra Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Inhibikase Therapeutics' return on equity of -42.80% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-53.14%	-34.94%
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A
Inhibikase Therapeutics	N/A	N/A	-$48.26M	-$0.43	N/A

59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 11.8% of Aldeyra Therapeutics shares are held by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Inhibikase Therapeutics had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 1 mentions for Inhibikase Therapeutics and 0 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 1.87 beat Inhibikase Therapeutics' score of 0.00 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aldeyra Therapeutics	Very Positive
Inhibikase Therapeutics	Neutral

Summary

Aldeyra Therapeutics beats Inhibikase Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Vanda Pharmaceuticals has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Aldeyra Therapeutics has lower revenue, but higher earnings than Vanda Pharmaceuticals. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$215.72M	1.44	-$220.47M	-$4.63	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A

Vanda Pharmaceuticals presently has a consensus target price of $13.70, indicating a potential upside of 167.06%. Aldeyra Therapeutics has a consensus target price of $5.50, indicating a potential upside of 304.41%. Given Aldeyra Therapeutics' higher possible upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Vanda Pharmaceuticals' average media sentiment score of 1.89 beat Aldeyra Therapeutics' score of 1.87 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Vanda Pharmaceuticals	Very Positive
Aldeyra Therapeutics	Very Positive

88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Aldeyra Therapeutics has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -127.41%. Vanda Pharmaceuticals' return on equity of -49.81% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Aldeyra Therapeutics	N/A	-53.14%	-34.94%

Summary

Vanda Pharmaceuticals beats Aldeyra Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Turn Therapeutics had 7 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 7 mentions for Turn Therapeutics and 0 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 1.87 beat Turn Therapeutics' score of 0.56 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Turn Therapeutics	Positive
Aldeyra Therapeutics	Very Positive

Turn Therapeutics is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A

Aldeyra Therapeutics' return on equity of -53.14% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	-230.84%	-53.19%
Aldeyra Therapeutics	N/A	-53.14%	-34.94%

Turn Therapeutics presently has a consensus price target of $9.00, indicating a potential downside of 39.76%. Aldeyra Therapeutics has a consensus price target of $5.50, indicating a potential upside of 304.41%. Given Aldeyra Therapeutics' higher probable upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Aldeyra Therapeutics beats Turn Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Amarin?

Amarin (NASDAQ:AMRN) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

22.3% of Amarin shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 4.2% of Amarin shares are owned by insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aldeyra Therapeutics has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$186.23M	1.55	-$38.80M	-$0.99	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A

Amarin has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Aldeyra Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
Aldeyra Therapeutics	N/A	-53.14%	-34.94%

Amarin presently has a consensus target price of $13.00, suggesting a potential downside of 4.62%. Aldeyra Therapeutics has a consensus target price of $5.50, suggesting a potential upside of 304.41%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Amarin's average media sentiment score of 1.87 equaled Aldeyra Therapeutics'average media sentiment score.

Company	Overall Sentiment
Amarin	Very Positive
Aldeyra Therapeutics	Very Positive

Summary

Aldeyra Therapeutics beats Amarin on 10 of the 13 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Zentalis Pharmaceuticals?

Aldeyra Therapeutics (NASDAQ:ALDX) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aldeyra Therapeutics has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.85, meaning that its share price is 85% more volatile than the broader market.

Aldeyra Therapeutics' return on equity of -53.14% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-53.14%	-34.94%
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A
Zentalis Pharmaceuticals	N/A	N/A	-$137.06M	-$1.95	N/A

Aldeyra Therapeutics currently has a consensus target price of $5.50, indicating a potential upside of 304.41%. Zentalis Pharmaceuticals has a consensus target price of $6.75, indicating a potential upside of 117.04%. Given Aldeyra Therapeutics' higher possible upside, research analysts plainly believe Aldeyra Therapeutics is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Zentalis Pharmaceuticals had 4 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 0 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 1.87 beat Zentalis Pharmaceuticals' score of 0.53 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aldeyra Therapeutics	Very Positive
Zentalis Pharmaceuticals	Positive

Summary

Aldeyra Therapeutics beats Zentalis Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Aldeyra Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALDX vs. The Competition

Export

Metric	Aldeyra Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$82.04M	$12.39B	$7.18B	$13.74B
Dividend Yield	N/A	2.64%	2.57%	12.64%
P/E Ratio	-3.49	797.25	274.66	25.48
Price / Sales	N/A	801.14	683.57	100.94
Price / Cash	N/A	87.33	77.01	51.20
Price / Book	1.84	10.49	10.45	6.33
Net Income	-$33.85M	$2.81B	$3.48B	$358.24M
7 Day Performance	1.49%	2.83%	0.88%	1.20%
1 Month Performance	-12.26%	3.30%	0.03%	-2.04%
1 Year Performance	-72.85%	3.58%	18.28%	5.41%

Aldeyra Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALDX Aldeyra Therapeutics	2.7328 of 5 stars	$1.36 -1.4%	$5.50 +304.4%	-71.8%	$83.25M	N/A	N/A	6	Positive News
IKT Inhibikase Therapeutics	1.5626 of 5 stars	$2.50 flat	$5.40 +116.0%	+47.4%	$348.84M	$260K	N/A	6	News Coverage Positive News
VNDA Vanda Pharmaceuticals	3.1107 of 5 stars	$5.43 flat	$13.70 +152.3%	+16.4%	$328.31M	$216.10M	N/A	290	Positive News
TTRX Turn Therapeutics	1.6963 of 5 stars	$9.80 flat	$8.00 -18.4%	N/A	$291.92M	N/A	N/A	2
AMRN Amarin	1.2792 of 5 stars	$13.63 flat	$13.00 -4.6%	-5.0%	$287.90M	$213.65M	N/A	360	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALDX) was last updated on 9/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aldeyra Therapeutics (ALDX) Competitors

ALDX vs. IKT, VNDA, TTRX, AMRN, and ZNTL

How does Aldeyra Therapeutics compare to Inhibikase Therapeutics?

Summary

How does Aldeyra Therapeutics compare to Vanda Pharmaceuticals?

Summary

How does Aldeyra Therapeutics compare to Turn Therapeutics?

Summary

How does Aldeyra Therapeutics compare to Amarin?

Summary

How does Aldeyra Therapeutics compare to Zentalis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX vs. The Competition

Aldeyra Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aldeyra Therapeutics (ALDX) Competitors

ALDX vs. IKT, VNDA, TTRX, AMRN, and ZNTL

How does Aldeyra Therapeutics compare to Inhibikase Therapeutics?

Do analysts prefer ALDX or IKT?

Which has more volatility & risk, ALDX or IKT?

Is ALDX or IKT more profitable?

Which has stronger earnings & valuation, ALDX or IKT?

Do institutionals and insiders have more ownership in ALDX or IKT?

Does the media prefer ALDX or IKT?

Summary

How does Aldeyra Therapeutics compare to Vanda Pharmaceuticals?

Which has more risk & volatility, VNDA or ALDX?

Which has stronger valuation & earnings, VNDA or ALDX?

Do analysts prefer VNDA or ALDX?

Does the media refer more to VNDA or ALDX?

Do insiders & institutionals believe in VNDA or ALDX?

Is VNDA or ALDX more profitable?

Summary

How does Aldeyra Therapeutics compare to Turn Therapeutics?

Do insiders and institutionals believe in TTRX or ALDX?

Does the media refer more to TTRX or ALDX?

Which has better earnings and valuation, TTRX or ALDX?

Is TTRX or ALDX more profitable?

Do analysts prefer TTRX or ALDX?

Summary

How does Aldeyra Therapeutics compare to Amarin?

Do institutionals & insiders believe in AMRN or ALDX?

Which has preferable valuation & earnings, AMRN or ALDX?

Which has more risk and volatility, AMRN or ALDX?

Is AMRN or ALDX more profitable?

Do analysts rate AMRN or ALDX?

Does the media refer more to AMRN or ALDX?

Summary

How does Aldeyra Therapeutics compare to Zentalis Pharmaceuticals?

Do insiders & institutionals have more ownership in ALDX or ZNTL?

Which has more volatility and risk, ALDX or ZNTL?

Is ALDX or ZNTL more profitable?

Which has preferable valuation and earnings, ALDX or ZNTL?

Do analysts rate ALDX or ZNTL?

Does the media refer more to ALDX or ZNTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX vs. The Competition

Aldeyra Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools